Ardelyx appoints Jeremy Caldwell as executive vice president and chief scientific officer

11 December 2014

Biopharma commpany Ardelyx (Nasdaq: ARDX) has appointed Jeremy Caldwell as executive vice president and chief scientific officer.

Mike Raab, president and chief executive, said: "Jeremy has played a key role in advancing breakthrough discovery and research platforms in life sciences innovation, and we are extremely pleased to announce he is joining our team. His insights and expertise will be instrumental during this pivotal time for Ardelyx as we seek to further expand our research engine and continue to leverage our proprietary pipeline in disease areas with substantial unmet needs."

Dr Caldwell has 20 years of experience in bringing therapies to the clinic, and was most recently entrepreneur-in-residence at Third Rock Ventures where he focused on the formation and development of life science companies. Prior to this, he held positions at Merck (NYSE: MRK) amd Novartis (NOVN: VX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK